IMTX
Immatics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMTX
Immatics N.V.
A clinical-stage biotechnology company that developing T cell receptor-based immunotherapies for the treatment of cancer
Biological Technology
03/10/2020
07/02/2020
NASDAQ Stock Exchange
297
12-31
Common stock
Paul-Ehrlich-Strabe 15, 72076 Tübingen, Federal Republic of Germany
--
Immatics N.V., established on March 10, 2020, is a Dutch private limited liability company. The company is a biopharmaceutical company focused on the development of T-cell receptor-based immunotherapies.
Company Financials
EPS
IMTX has released its 2025 Q2 earnings. EPS was reported at -0.66, versus the expected -0.36, missing expectations. The chart below visualizes how IMTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IMTX has released its 2025 Q3 earnings report, with revenue of 6.09M, reflecting a YoY change of -89.20%, and net profit of -59.31M, showing a YoY change of -903.22%. The Sankey diagram below clearly presents IMTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
